Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SNYR vs HSIC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSIC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

HSIC Overall Winner 6-Pillar Tally: SNYR 2 – 4 HSIC Matrix Metrics: SNYR 2 – 8 HSIC

As of Nov 20, 2026, Henry Schein Inc (HSIC) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas HSIC carries 50.9/100 (HOLD) at $83.52 (13.9x Forward P/E, 5.8% operating margin).

  • Technical & Structure Timing Caution: SNYR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile HSIC is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNYR vs HSIC
SNYR NASDAQ
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14
HSIC NASDAQ Head-to-Head Winner
Henry Schein Inc
Wholesale-Medical, Dental & Hospital Equipment & Supplies
$83.52
-1.51% 1D
Market Cap $9.4B
TTM Revenue $13.7B
Forward P/E 13.9x
Beta / 30D Vol 0.55β · 40% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 50.0 Fund 53.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.7%) with fading momentum, RSI 45
RSI-14: 44.5 · SMA20: $85.68 · SMA50: $85.50

6-Pillar Scorecard Institutional Category Breakdown (SNYR 2 – 4 HSIC)

Columns: Metric · SNYR · HSIC
1. Valuation Multiples SNYR
Forward P/E 0.6x 13.9x
Trailing P/E 0.6x 23.2x
PEG Ratio N/M 1.67x
EV / Revenue 0.1x 1.0x
2. Growth & Scale HSIC
Revenue Growth (YoY) -32.8% +4.0%
Earnings Growth (YoY) -90.6% +26.2%
TTM Revenue (USD) $28M $13.7B
Market Cap $4.1M $9.4B
3. Profitability & Quality HSIC
Gross Margin 65.4% 31.6%
Operating Margin -10.3% 5.8%
Net Profit Margin -57.0% 3.1%
Return on Equity (ROE) -361.1% 9.2%
4. Balance Sheet & Cash Flow HSIC
Cash Generation (TTM) -$3.8M $500M
Cash Flow Margin -13.7% 3.6%
Net Cash / Leverage -361.1% ROE $3.71B Net Debt (1.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HSIC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 29.4% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity 75.7% of Rev ($21M) 25.8% of Rev ($3.54B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNYR (2) vs HSIC (8)
Institutional Metric SNYR HSIC Criterion Row Edge
Market Capitalization
Scale
$4.1M $9.4B Larger Scale HSIC
Trailing P/E Ratio
Valuation
0.6x 23.2x Lower Multiple SNYR
Forward P/E Ratio
Valuation
0.6x 13.9x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
-32.8% +4.0% Higher Growth HSIC
Operating Margin (TTM)
Profitability
-10.3% 5.8% Higher Margin HSIC
Net Profit Margin
Profitability
-57.0% 3.1% Higher Margin HSIC
Return on Equity (ROE)
Capital Efficiency
-361.1% 9.2% Higher ROE HSIC
52-Week Range Position
Momentum
1% ($0–$3) 63% ($69–$92) Stronger Trend HSIC
Beta / 30D Volatility
Risk Regime
-0.86β · 868% Vol 0.55β · 40% Vol Lower Realized Risk HSIC
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 50.9 / 100 (HOLD) Higher Composite HSIC
Trailing 12M Revenue (USD)
Operating Scale
$28M $13.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.4% 31.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev 1.67x PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.8M (-361.1% ROE) $500M ($3.71B Net Debt (1.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HSIC +11.58 pp
SNYR: -16.28% · HSIC: -4.7%
3M Horizon HSIC +62.98 pp
SNYR: -56.64% · HSIC: +6.34%
6M Horizon HSIC +109.5 pp
SNYR: -93.2% · HSIC: +16.3%
1Y Horizon HSIC +116.58 pp
SNYR: -96.13% · HSIC: +20.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SNYR Revenue HSIC Revenue SNYR Op. Margin HSIC Op. Margin Margin Leader
FY2018 $30M $9.42B -14.5% 6.4% HSIC
FY2019 $30M $9.99B -27.1% 7.2% HSIC
FY2020 N/A $10.1B N/A 5.3% HSIC
FY2021 N/A $12.4B N/A 6.9% HSIC
FY2022 N/A $12.7B N/A 5.9% HSIC
FY2023 $40M $12.3B 25.3% 5.0% SNYR
FY2024 $30M $12.7B 16.7% 4.9% SNYR
FY2025 $30M $13.2B -27.8% 5.0% HSIC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HSIC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 29.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact HSIC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published
HSIC Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $9.4B market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 25.8% of Rev ($3.54B)
90D Engineering Disclosures 0 Published

Investor FAQ SNYR vs HSIC Key Questions & Quantitative Answers

As of Nov 20, 2026, Henry Schein Inc (HSIC) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas HSIC carries 50.9/100 (HOLD) at $83.52 (13.9x Forward P/E, 5.8% operating margin). Technical & Structure Timing Caution: SNYR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile HSIC is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSIC leads the Growth & Scale pillar: SNYR posts -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin), compared with HSIC at +4.0% YoY revenue growth and +26.2% YoY earnings growth on $13.7B TTM revenue (31.6% gross margin, 5.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SNYR cumulative revenue shifted +0.0% while HSIC shifted +39.9%. In operating R&D and SG&A reinvestment, SNYR deploys 75.7% of Rev ($21M) (0 90-day corporate R&D disclosures) versus 25.8% of Rev ($3.54B) (0 disclosures) for HSIC.

SNYR screens cheaper on headline valuation multiples. SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin), whereas HSIC trades at 13.9x Forward P/E, 23.2x Trailing P/E, 1.67x PEG, and 1.0x EV/Revenue (3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNYR (-361.1% ROE) versus HSIC (9.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk). By comparison, HSIC carries 29.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.